Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11402090rdf:typepubmed:Citationlld:pubmed
pubmed-article:11402090lifeskim:mentionsumls-concept:C0600688lld:lifeskim
pubmed-article:11402090lifeskim:mentionsumls-concept:C0205332lld:lifeskim
pubmed-article:11402090lifeskim:mentionsumls-concept:C1514468lld:lifeskim
pubmed-article:11402090lifeskim:mentionsumls-concept:C0598528lld:lifeskim
pubmed-article:11402090lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:11402090lifeskim:mentionsumls-concept:C0444930lld:lifeskim
pubmed-article:11402090pubmed:dateCreated2001-6-12lld:pubmed
pubmed-article:11402090pubmed:abstractTextMost studies on uraemic toxins have focused on disorders of enzymatic biochemistry. Recent studies to elucidate the pathogenesis of dialysis-related amyloidosis have provided new insights in progressive, irreversible protein modifications resulting from non-enzymatic biochemistry in uraemia. This paper focuses on two types of irreversible alterations of proteins: advanced glycation and lipoxidation. We investigate the causal role of various reactive carbonyl compounds (RCOs) accumulating in the serum, speculate on its clinical consequences, and discuss the therapeutic perspectives.lld:pubmed
pubmed-article:11402090pubmed:languageenglld:pubmed
pubmed-article:11402090pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11402090pubmed:citationSubsetIMlld:pubmed
pubmed-article:11402090pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11402090pubmed:statusMEDLINElld:pubmed
pubmed-article:11402090pubmed:issn0931-0509lld:pubmed
pubmed-article:11402090pubmed:authorpubmed-author:KurokawaKKlld:pubmed
pubmed-article:11402090pubmed:authorpubmed-author:MiyataTTlld:pubmed
pubmed-article:11402090pubmed:authorpubmed-author:SaitoAAlld:pubmed
pubmed-article:11402090pubmed:authorpubmed-author:van...lld:pubmed
pubmed-article:11402090pubmed:issnTypePrintlld:pubmed
pubmed-article:11402090pubmed:volume16 Suppl 4lld:pubmed
pubmed-article:11402090pubmed:ownerNLMlld:pubmed
pubmed-article:11402090pubmed:authorsCompleteYlld:pubmed
pubmed-article:11402090pubmed:pagination8-11lld:pubmed
pubmed-article:11402090pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:11402090pubmed:meshHeadingpubmed-meshheading:11402090...lld:pubmed
pubmed-article:11402090pubmed:meshHeadingpubmed-meshheading:11402090...lld:pubmed
pubmed-article:11402090pubmed:meshHeadingpubmed-meshheading:11402090...lld:pubmed
pubmed-article:11402090pubmed:meshHeadingpubmed-meshheading:11402090...lld:pubmed
pubmed-article:11402090pubmed:meshHeadingpubmed-meshheading:11402090...lld:pubmed
pubmed-article:11402090pubmed:meshHeadingpubmed-meshheading:11402090...lld:pubmed
pubmed-article:11402090pubmed:meshHeadingpubmed-meshheading:11402090...lld:pubmed
pubmed-article:11402090pubmed:year2001lld:pubmed
pubmed-article:11402090pubmed:articleTitleAdvanced glycation and lipoxidation end products: reactive carbonyl compounds-related uraemic toxicity.lld:pubmed
pubmed-article:11402090pubmed:affiliationInstitute of Medical Sciences and Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa 259-11, Japan.lld:pubmed
pubmed-article:11402090pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11402090pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11402090lld:pubmed